EE374 Budget Impact of Adalimumab Sandoz (BIOSIMILAR) in Comparison to Adalimumab- Reference Product in the Management of Autoimmune Diseases in Dubai
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.622
https://www.valueinhealthjournal.com/article/S1098-3015(22)00823-3/fulltext
Title :
EE374 Budget Impact of Adalimumab Sandoz (BIOSIMILAR) in Comparison to Adalimumab- Reference Product in the Management of Autoimmune Diseases in Dubai
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00823-3&doi=10.1016/j.jval.2022.04.622
First page :
Section Title :
Open access? :
No
Section Order :
10557